• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by AbbVie Inc.

    8/14/24 4:09:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    S-8 1 tm2420586d1_s8.htm FORM S-8

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ABBVIE INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

         
    Delaware   32-0375147

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer Identification No.)

     

    1 North Waukegan Road

    North Chicago, Illinois 60064-6400

    (847) 932-7900

    (Address of principal executive offices, including zip code)

     

     

    Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan

    (Full title of the plan)

     

     

    Perry C. Siatis, Esq.

    Executive Vice President, General Counsel and Secretary

    AbbVie Inc.

    1 North Waukegan Road

    North Chicago, Illinois 60064-6400

    (847) 932-7900

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Sophia Hudson, P.C.

    Zoey Hitzert

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    (212) 446-4800

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   x   Accelerated filer   ¨
           
    Non-accelerated filer   ¨   Smaller reporting company   ¨
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected to use the extended transition period for complying with the new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    AbbVie Inc. (“AbbVie” or the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) relating to shares of common stock of the Registrant, par value $0.01 per share (the “Common Stock”), that may be issued pursuant to awards outstanding under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the “Cerevel Plan”).

     

    On December 6, 2023, AbbVie entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Cerevel Therapeutics Holdings, Inc. (“Cerevel”), Symphony Harlan Merger Sub Inc. and Symphony Harlan LLC. On August 1, 2024, AbbVie completed the acquisition of Cerevel pursuant to the Merger Agreement.

     

    In connection with and upon the consummation of the transactions contemplated by the Merger Agreement and in accordance with the Merger Agreement, the Cerevel Plan was assumed by the Registrant and certain restricted stock unit awards in respect of shares of Cerevel common stock granted under the Cerevel Plan that remained outstanding under the Cerevel Plan as of August 1, 2024 were converted into restricted stock unit awards in respect of Common Stock, which converted awards will continue to be subject to the terms of the Cerevel Plan following the consummation of the transactions contemplated by the Merger Agreement. This Registration Statement is being filed for the purpose of registering the Common Stock issuable upon the settlement of such converted awards.

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing information specified in Part I will be delivered in accordance with Form S-8 and Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the “SEC”), either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the SEC are incorporated by reference in this Registration Statement:

     

      (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 20, 2024 (including the information in Part III incorporated by reference from the Registrant’s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on March 18, 2024);

     

      (b)

    The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the SEC on May 3, 2024;

     

      (c)

    The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, as filed with the SEC on August 7, 2024;

     

      (d) The Registrant’s Current Reports on Form 8-K as filed with the SEC on February 20, 2024, February 26, 2024 and May 8, 2024; and

     

      (e) The description of the Registrant’s Common Stock which is contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 20, 2024, including any amendment or report filed for the purpose of updating such description.

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all of such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any documents, portions of documents, exhibits or other information that is deemed to be furnished and not filed under such provisions.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    As permitted by the Delaware General Corporation Law (the “DGCL”), the Registrant’s amended and restated certificate of incorporation provides that a director of the Registrant will not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

     

    · for any breach of their duty of loyalty to the Registrant or its stockholders;

     

     

     

     

    · for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
    · under Section 174 of the DGCL relating to unlawful payments of dividends or unlawful stock repurchases or redemptions; or
    · for any transaction from which the director derived an improper personal benefit.

     

    The limitation of liability does not apply to liabilities arising under the federal or state securities laws and does not affect the availability of equitable remedies, such as injunctive relief or rescission.

     

    The Registrant’s amended and restated certificate of incorporation and by-laws include provisions that indemnify, to the fullest extent allowable under the DGCL, the personal liability of directors or officers for monetary damages for actions taken as a director or officer of the Registrant, or for serving at the Registrant’s request as a director or officer or another position at another corporation or enterprise, as the case may be. The Registrant’s amended and restated certificate of incorporation and by-laws also provide that the Registrant must indemnify and advance reasonable expenses to its directors and officers, subject to its receipt of an undertaking from the indemnified party as may be required under the DGCL. The Registrant’s amended and restated by-laws expressly authorize the Registrant to carry directors’ and officers’ insurance to protect the Registrant, its directors, officers and certain employees from some liabilities.

     

    The foregoing is only a general summary of certain aspects of Delaware law and the Registrant’s amended and restated certificate of incorporation and by-laws dealing with indemnification of directors and officers and does not purport to be complete. It is qualified in its entirety by reference to the detailed provisions of those sections of the DGCL referenced above and the amended and restated certificate of incorporation and by-laws of the Registrant.

     

    Item 7. Exemption from Registration Claimed.

     

    Not Applicable.

     

    Item 8. Exhibits.

     

    The information required by this Item is set forth in the Exhibits Index that precedes the signature page of this Registration Statement.

     

    Item 9. Undertakings.

     

    (a)            The undersigned registrant hereby undertakes:

     

    (1)            To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)            To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii)           To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii)          To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (2)            That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)            To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

     

     

    (b)            The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)            Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    EXHIBIT INDEX

     

            Incorporated by Reference Herein    
                 
    Exhibit 
    Number
      Description   Form   Filing Date   Filed
    Herewith
    4.1   Amended and Restated Certificate of Incorporation.   AbbVie Inc. Current Report on Form 8-K (Commission File No. 001-35565)   January 2, 2013    
    4.2   Second Amended and Restated Bylaws.   AbbVie Inc. Current Report on Form 8-K (Commission File No. 001-35565)   October 14, 2022    
    4.3   Description of Common Stock.   AbbVie Inc. Annual Report on Form 10-K (Commission File No. 001-35565)   February 20, 2024    
    4.4   Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan.           X
    5.1   Opinion of Kirkland & Ellis LLP.           X
    23.1   Consent of Kirkland & Ellis LLP (included in Exhibit 5.1).           X
    23.2   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.           X
    24.1   Power of Attorney (included in the signature page to this Registration Statement).           X
    107   Filing Fee Table.           X

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in North Chicago, Illinois, on this 14th day of August 2024.

     

      AbbVie Inc.
         
      By: /s/ Scott T. Reents
        Scott T. Reents
        Executive Vice President, Chief Financial Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Robert A. Michael, Perry C. Siatis, and Scott T. Reents, and each of them, with full power of substitution and full power to act without the others, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
         
    /s/ Robert A. Michael   Chief Executive Officer and Director
    (Principal Executive Officer)
      August 14, 2024
    Robert A. Michael        
         
    /s/ Scott T. Reents   Executive Vice President, Chief Financial
    Officer
    (Principal Financial Officer)
      August 14, 2024
    Scott T. Reents        
         
    /s/ Kevin K. Buckbee   Senior Vice President, Controller
    (Principal Accounting Officer)
      August 14, 2024
    Kevin K. Buckbee        
         
    /s/ Richard A. Gonzalez  Executive Chairman of the Board   August 14, 2024
    Richard A. Gonzalez    
           
    /s/ Robert J. Alpern, M.D.   Director   August 14, 2024
    Robert J. Alpern, M.D.        
         
    /s/ Roxanne S. Austin   Director   August 14, 2024
    Roxanne S. Austin        
         
    /s/ William H.L. Burnside   Director   August 14, 2024
    William H.L. Burnside        
             
    /s/ Jennifer L. Davis   Director   August 14, 2024
    Jennifer L. Davis    

     

     

     

     

    /s/ Thomas C. Freyman   Director   August 14, 2024
    Thomas C. Freyman        
         
    /s/ Brett J. Hart   Director   August 14, 2024
    Brett J. Hart        
         
    /s/ Melody B. Meyer   Director   August 14, 2024
    Melody B. Meyer        
             
    /s/ Susan E. Quaggin, M.D.   Director   August 14, 2024
    Susan E. Quaggin, M.D.        
         
    /s/ Edward J. Rapp   Director   August 14, 2024
    Edward J. Rapp        
             
    /s/ Rebecca B. Roberts   Director   August 14, 2024
    Rebecca B. Roberts        
             
    /s/ Glenn F. Tilton   Director   August 14, 2024
    Glenn F. Tilton        
             
    /s/ Frederick H. Waddell   Director   August 14, 2024
    Frederick H. Waddell        

     

     

     

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    11/4/2025$237.00Buy → Hold
    DZ Bank
    10/14/2025Buy → Hold
    Erste Group
    10/1/2025Buy → Hold
    HSBC Securities
    9/17/2025$270.00Hold → Buy
    Berenberg
    More analyst ratings

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

    The nationwide program invites eligible Natrelle® breast augmentation and reconstruction patients to share their personal experiences.Natrelle® champions women's voices to provide support at every step of their breast aesthetics journey.IRVINE, Calif., Feb. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the launch of the Faces of Natrelle® Testimonial Program, a nationwide initiative inviting women to share their real stories and experiences with Natrelle® breast implants to help educate, empower, and support others considering breast surgery.

    2/3/26 8:50:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

    Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement in total body re-pigmentation (T-VASI 50) and at least a 75% improvement in facial re-pigmentation (F-VASI 75) from baseline at week 48.1If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune disease. NORTH CHICAGO, Ill., Feb. 3, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA)

    2/3/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:15 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alpern Robert J

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:18 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:10 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on AbbVie with a new price target

    UBS resumed coverage of AbbVie with a rating of Neutral and set a new price target of $240.00

    1/7/26 9:08:42 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded AbbVie from Hold to Buy and set a new price target of $265.00

    12/10/25 8:10:03 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    2/4/26 7:54:33 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    1/7/26 4:08:59 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by AbbVie Inc.

    10-Q - AbbVie Inc. (0001551152) (Filer)

    11/4/25 2:05:49 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key t

    1/7/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Third-Quarter 2025 Financial Results

    Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues

    10/31/25 7:49:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care